JP4322933B2 - チロシンキナーゼ阻害剤が惹起する皮膚障害の予防剤および／または処置剤 - Google Patents

チロシンキナーゼ阻害剤が惹起する皮膚障害の予防剤および／または処置剤 Download PDF

Info

Publication number
JP4322933B2
JP4322933B2 JP2007060415A JP2007060415A JP4322933B2 JP 4322933 B2 JP4322933 B2 JP 4322933B2 JP 2007060415 A JP2007060415 A JP 2007060415A JP 2007060415 A JP2007060415 A JP 2007060415A JP 4322933 B2 JP4322933 B2 JP 4322933B2
Authority
JP
Japan
Prior art keywords
tyrosine kinase
kinase inhibitor
agent
egfr tyrosine
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007060415A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007246523A5 (enExample
JP2007246523A (ja
Inventor
成紀 金
和之 山口
芳美 木下
昌作 野村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP2007060415A priority Critical patent/JP4322933B2/ja
Publication of JP2007246523A publication Critical patent/JP2007246523A/ja
Publication of JP2007246523A5 publication Critical patent/JP2007246523A5/ja
Application granted granted Critical
Publication of JP4322933B2 publication Critical patent/JP4322933B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2007060415A 2007-03-09 2007-03-09 チロシンキナーゼ阻害剤が惹起する皮膚障害の予防剤および／または処置剤 Expired - Fee Related JP4322933B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007060415A JP4322933B2 (ja) 2007-03-09 2007-03-09 チロシンキナーゼ阻害剤が惹起する皮膚障害の予防剤および／または処置剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007060415A JP4322933B2 (ja) 2007-03-09 2007-03-09 チロシンキナーゼ阻害剤が惹起する皮膚障害の予防剤および／または処置剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006073022A Division JP4091639B2 (ja) 2006-03-16 2006-03-16 チロシンキナーゼ阻害剤が惹起する皮膚障害の予防剤および／または処置剤

Publications (3)

Publication Number Publication Date
JP2007246523A JP2007246523A (ja) 2007-09-27
JP2007246523A5 JP2007246523A5 (enExample) 2009-01-08
JP4322933B2 true JP4322933B2 (ja) 2009-09-02

Family

ID=38591186

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007060415A Expired - Fee Related JP4322933B2 (ja) 2007-03-09 2007-03-09 チロシンキナーゼ阻害剤が惹起する皮膚障害の予防剤および／または処置剤

Country Status (1)

Country Link
JP (1) JP4322933B2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105311029A (zh) * 2014-06-06 2016-02-10 正大天晴药业集团股份有限公司 抗肿瘤活性的喹啉衍生物

Also Published As

Publication number Publication date
JP2007246523A (ja) 2007-09-27

Similar Documents

Publication Publication Date Title
AU2018262891B2 (en) Combination therapy
Knox et al. A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix
JP2020019780A (ja) Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬
JP7223998B2 (ja) Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
JP2023065622A (ja) 重度腎機能障害を有する癌患者に対する治療方法
CA2868677A1 (en) Dexanabinol or a derivative thereof for use in the treatment of cancer in dose ranges of 2-30 mg/kg
US20180042891A1 (en) Cancer Cell Apoptosis
JP6826737B2 (ja) がん患者の治療に有用な尿のアルカリ剤
CA3124316C (en) Cancer treatment using docetaxel by controlling peak plasma levels
JP4091639B2 (ja) チロシンキナーゼ阻害剤が惹起する皮膚障害の予防剤および／または処置剤
CN114177299A (zh) 包含ezh2抑制剂和scd1抑制剂的抗肿瘤药物组合物及其用途
JP4322933B2 (ja) チロシンキナーゼ阻害剤が惹起する皮膚障害の予防剤および／または処置剤
JP2010106019A (ja) リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および／または症状軽減剤
SG191926A1 (en) Combinations
JP2007246523A5 (enExample)
US20070269531A1 (en) Non-Steroid Anti-Inflammatory Agents with Vitamins, Minerals, and Dietary Supplements for the Prevention and Treatment of Primary, Secondary and Tertiary Cancer
KR102528732B1 (ko) 포지오티닙 및 칼슘채널 억제제를 포함하는 암의 예방 또는 치료용 약학적 조성물
CN105228611B (zh) 用于治疗或预防头颈癌的pi3激酶抑制剂与紫杉醇的组合
CN118159538A (zh) 含met受体酪氨酸激酶抑制剂的药物组合及应用
HK40018197A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
WO2021081081A1 (en) Methods of treating, ameliorating, and/or preventing cancer using pyrvinium compositions
NZ788180A (en) Combination therapy with notch and pd-1 or pd-l1 inhibitors
HK1204976B (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
JP2011116728A (ja) 膵癌に対するラパチニブとｔｓ−１の併用療法
CN101137386A (zh) 肝癌的治疗方法

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081117

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20081117

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20081211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081224

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090526

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090603

R150 Certificate of patent or registration of utility model

Ref document number: 4322933

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120612

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150612

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees